Intracutaneous Reactivity Test for Medical Plastics: Standards, Methodology, and Biological Safety E

The intracutaneous reactivity test is a cornerstone biological safety evaluation for medical plastics, designed to determine whether extractable substances from polymeric materials can cause localized tissue irritation upon contact with living skin. Conducted in accordance with ISO 10993-10 and the Chinese national standard GB/T 16886.10, this test is a mandatory component of biocompatibility assessment for medical devices intended for skin, mucosal, or breached-surface contact. This article provides a comprehensive technical overview of sample preparation, testing methodology, scoring criteria, and regulatory applications of the intracutaneous reactivity test for medical plastic materials.

Technical Overview

The intracutaneous reactivity test, also known as the intradermal irritation test, is an in vivo biological evaluation used to assess the irritation potential of medical plastic materials and medical devices. The test determines whether chemical substances that migrate (leach or extract) from a plastic material during simulated clinical use can provoke a localized inflammatory response—specifically erythema (redness) and edema (swelling)—when injected into the dermal layer of test animals.

This test is specified in ISO 10993-10, Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization, and its Chinese equivalent GB/T 16886.10. It is categorized as a supplemental irritation test, typically required when a medical plastic device has direct or indirect contact with skin, mucous membranes, breached surfaces, or internal tissues. Because medical plastics such as PVC, polyethylene, polypropylene, polycarbonate, polyurethane, and silicone elastomers may contain plasticizers, stabilizers, colorants, residual monomers, sterilant residues, or processing aids, evaluating their extractable chemical burden for irritation potential is critical for demonstrating biological safety.

The test follows a comparative design: extracts of the test material are injected intradermally at multiple sites on the backs of healthy albino rabbits, while blank extraction vehicles (without test material) are injected at adjacent control sites. The tissue reactions at both sites are scored blind against a standardized grading scale at defined observation intervals. If the reaction at the test extract site does not exceed that of the corresponding control site beyond the acceptance threshold, the material is considered non-irritant.

Testing Samples

Intracutaneous reactivity testing applies to a broad range of medical plastic materials and finished devices. Samples should be representative of the final product in its sterilized, ready-to-use condition, since sterilization methods such as ethylene oxide (EtO), gamma irradiation, or steam autoclaving can alter the extractable profile of polymers.

Catheters, Tubing, and Fluid Path Components

Intravenous catheters, urinary catheters, endotracheal tubes, infusion sets, extension lines, and blood tubing sets made from plasticized PVC or thermoplastic polyurethane are among the most frequently submitted sample types. These devices contact mucosal membranes and circulating blood indirectly, making irritation screening essential.

Syringes, Injection Components, and Drug Delivery Devices

Syringe barrels and plungers, pen injectors, insulin pump housings, nebulizer components, and prefilled syringe packaging systems composed of polypropylene, polycycloolefin, or polycarbonate require evaluation of extractables that may migrate into injected medicaments.

Films, Sheets, and Packaging Materials

Flexible films for infusion bags, wound dressings, adhesive backings, blister packaging, and sterile barrier systems are tested to confirm that contact with tissue or drug products does not elicit irritation from residual additives or processing chemicals.

Molded, Extruded, and 3D-Printed Polymer Components

Device housings, connectors, luer fittings, implants, orthopedic instrumentation, and additively manufactured surgical guides made from medical-grade resins are evaluated to verify that polymer formulation, printing resins, or post-processing residues do not produce irritant effects.

Raw Materials and Polymer Compounds

Resin pellets, masterbatches, and compounded plastic stock intended for medical device manufacturing can be screened at the material selection stage, allowing formulation risks to be identified before tooling and production investments are made.

Testing Items

The core scope of the intracutaneous reactivity test includes the following evaluation endpoints:

• Intracutaneous irritation potential of polar extracts of the medical plastic test sample
• Intracutaneous irritation potential of non-polar extracts of the medical plastic test sample
• Erythema and eschar formation grading at each injection site on a standardized 0–4 scale
• Edema formation grading at each injection site on a standardized 0–4 scale
• Comparative assessment of test extract sites versus blank vehicle control sites
• Calculation of the Primary Irritation Index (PII) and determination of the irritant classification
• Optional additional extraction vehicles, such as 5% alcohol in saline or polyethylene glycol 400, where clinically justified

Testing Methods

The standard test procedure, performed by accredited third-party laboratories and research institutions, consists of sample preparation, extraction, animal dosing, observation, and scoring, as described below.

Sample Preparation and Extraction

Test samples are prepared with a standardized surface-area-to-volume ratio in accordance with ISO 10993-12 (sampling of test samples and preparation of reference materials). For plastics, typical ratios are 3 cm² per milliliter of extraction vehicle for sheets with a thickness of 0.5 mm or less, 6 cm²/mL for thicknesses of 0.5–1.0 mm, and approximately 0.1–0.2 g/mL for irregular or three-dimensional specimens. Two extraction vehicles are used: a polar vehicle (typically physiological saline or water for injection) and a non-polar vegetable oil (such as cottonseed oil or sesame oil, freshly refined and of pharmacopoeial quality). Extraction is performed under one of the following standard conditions, selected to simulate or exceed clinical exposure:

• 37 °C for 24 hours (most common for plastics)
• 50 °C for 72 hours
• 70 °C for 24 hours
• 121 °C for 1 hour (for materials exposed to steam sterilization)

Blank control extracts are prepared in parallel by exposing each vehicle to a clean glass or inert container under identical extraction conditions.

Animal Selection and Injection Procedure

Healthy adult albino rabbits with clipped or depilated dorsal skin are used as the standard animal model, typically two or three animals per extract. The dorsal area on each side of the spine is prepared with a minimum of six injection sites per animal. Using a fine-gauge needle, 0.2 mL of the test extract is injected intradermally at each of five sites on one side, with the formation of a small bleb confirming correct deposition in the dermis. A corresponding series of 0.2 mL injections of the blank vehicle control is placed immediately adjacent to the test sites. In some protocols, additional sites receive injections of the extract to allow histamine- or irritant-positive control comparisons, supporting assay sensitivity verification.

Observation and Scoring Criteria

Injection sites are examined grossly at approximately 24, 48, and 72 hours after injection, and any other adverse reactions such as necrosis are recorded. Each site is graded independently for erythema/eschar and edema using the ISO 10993-10 scoring scale:

• Erythema and eschar: 0 = no erythema; 1 = very slight erythema; 2 = well-defined erythema; 3 = moderate erythema; 4 = severe erythema to eschar formation
• Edema: 0 = no edema; 1 = very slight edema; 2 = well-defined edema; 3 = moderate edema; 4 = severe edema extending beyond the raised area

Scoring is performed by trained observers under blinded conditions to minimize bias, and individual scores are documented for each observation interval and each animal.

Interpretation and Acceptance Criteria

The Primary Irritation Index is calculated as the sum of all erythema and edema scores for the test extract sites divided by the total number of scoring observations, and the same calculation is performed for the control sites. The material meets the requirements of the test if the difference between the mean scores of the test extract sites and the corresponding blank control sites is 1.0 or less (or does not exceed the control by a statistically significant margin where a larger number of animals is used). If the test response exceeds the control beyond the acceptance limit, the material is classified as an intracutaneous irritant, prompting formulation review, extraction characterization, or chemical analysis of irritant extractables such as residual monomers, acidic degradation products, or plasticizer additives.

Applications

Intracutaneous reactivity testing of medical plastics supports a wide range of product development and regulatory activities:

• Biocompatibility testing packages for regulatory submissions, including NMPA registration in China, FDA 510(k) and PMA submissions in the United States, and CE marking technical documentation under the EU Medical Device Regulation (MDR)
• Biological safety evaluation of surface-contacting devices such as electrode housings, compression sleeves, and protective covers
• Evaluation of external communicating devices, including infusion sets, dialysis tubing, and respiratory circuits that contact circulating blood or mucosal membranes indirectly
• Assessment of implant-grade polymers and long-term contacting plastic components as part of the ISO 10993-1 biological evaluation plan
• Supplier qualification and incoming material control programs for medical-grade resins and compounds
• Design change and process validation studies, including evaluation of new sterilization cycles, secondary processing, or recycled polymer content
• Root cause investigation of adverse tissue reactions or complaint events associated with plastic device components
• Research and development screening of novel polymer formulations, bio-based plastics, and additive systems before clinical device integration

FAQ

Which standards govern the intracutaneous reactivity test for medical plastics?

The test is performed according to ISO 10993-10 and GB/T 16886.10 for test methodology, with sample preparation governed by ISO 10993-12 and GB/T 16886.12. The United States Pharmacopoeia (USP) also historically specified intracutaneous tests in its biological reactivity chapters for plastic materials used in pharmaceutical containers.

What sample quantity is required for testing?

The required quantity depends on the surface area of the device. In general, a minimum of 120 cm² of material is recommended to support both polar and non-polar extraction at standard ratios, along with sterilized, finished-condition samples representative of the final product.

How long does the test take to complete?

Extraction requires up to 72 hours depending on the selected condition (24 hours at 37 °C is most common), the in-life observation phase lasts 72 hours after dosing, and the full study, including animal acclimatization and report preparation, is typically completed within three to four weeks.

When is intracutaneous testing required versus other irritation tests?

Intracutaneous testing is typically required for devices contacting breached or compromised skin, mucosal membranes, or internal tissues, and where the irritant potential cannot be confirmed by other means. For intact-skin surface devices, alternatives such as the reconstructed human epidermis (RhE) in vitro skin irritation test under ISO 10993-23 may be acceptable, and an ISO 10993-1 based risk assessment or chemical toxicological evaluation may sometimes justify waiving in vivo testing entirely.

What does a failed result indicate for a medical plastic material?

A result exceeding the control response by more than the acceptance threshold indicates the presence of irritant extractables. Common causes include residual monomers, acidic or alkaline degradation products, excess plasticizers, mold release agents, sterilant residues such as ethylene oxide or ethylene chlorohydrin, or inadequate post-curing. Corrective actions may include process optimization, alternative material grades, improved sterilization aeration, or comprehensive extractables and leachables (E&L) chemical characterization.